Evidence map›Paper›PMID 42563462›Full record

ArticleActa dermato-venereologica2026

Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry.

Stephan Traidl, Angela Cornelius, Luise Heinrich, Doreen Siegels, Helena Zacharias, Annice Heratizadeh, Tatjana Honstein, Barbara Kind, Dora Stölzl, Matthias Augustin and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Stephan TraidlDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany. traidl.stephan@mh-hannover.de.ORCID 0000-0003-4806-599X
Angela CorneliusDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
Luise HeinrichCenter for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany.
Doreen SiegelsCenter for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany.
Helena ZachariasPeter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Hannover Medical School, 30625 Hannover, Germany.
Annice HeratizadehDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
Tatjana HonsteinDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
Barbara KindCenter for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany.
Dora StölzlCenter for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Matthias AugustinInstitute for Health Services Research in Dermatology Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
Thomas SchaeferPractice Dr. med. Thomas Schaefer and Dr. med. Doreen Belz, Derma Koeln, Cologne, Germany.
Anne BongPractice Dr. med. Anne Bong, Emmerich, Germany.
Susanne AbrahamCenter for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany; Department of Dermatology, University Allergy Center, Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany.
Andreas PinterDepartment of Dermatology, Venereology and Allergology, Clinical Research, University Hospital, Frankfurt am Main, Germany.
Jutta Ramaker-BrunkePractice 'Die Hautärzte' Braunschweig, Braunschweig, Germany.
Michael Schulz-KiesowPractice Dr. med. Michael Schulz-Kiesow and Dr. med. Inken Reimers, Lübeck, Germany.
Sven QuistDermatology Clinic, Helix Medical Excellence Center Mainz, Mainz, Germany.
Beate SchwarzPractice Dr. med. Beate Schwarz, Langenau, Germany.
Tilo BiedermannDepartment of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
Mohammad AsefiDermatology study center Hunsrueck, Simmern, Germany.
Caroline MannClinic for Dermatology, University Hospital, Mainz, Germany.
Nicole AdlerHautärzte am Fastnachtsbrunnen, FÄ Nicole Adler, Mainz, Germany.
Michael SticherlingDepartment of Dermatology, University, German Center for Immunotherapy, Erlangen, Germany.
Knut SchäkelDepartment of Dermatology, University Hospital, Heidelberg, Germany.
Anke HerrmannPractice Dr. med. Anke Herrmann, Greifswald, Germany.
Kathrin MeinhardtPractice Kathrin Meinhardt, Beckum, Germany.
Maren StahlPractice Dr. med. Maren Stahl, Ostero, Germany.
Christiane HandrickPractice Dr. med. Christiane Handrick, Berlin, Germany.
Sabine AndersPractice Dr. med. Sabine Anders, Munich, Germany.
Stephan WeidingerCenter for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Jochen SchmittCenter for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany.
Thomas WerfelDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
TREATgermany study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis is commonly associated with depressive symptoms and fatigue, which significantly impact quality of life. While clinical trials suggest beneficial effects of dupilumab on mental health, real-world evidence remains limited. This longitudinal cohort study analysed data from adult patients treated with dupilumab in the TREATgermany registry. Subgroups were defined by baseline Center for Epidemiologic Studies Depression Scale (CES D) scores ≥16 (clinically significant depressive symptoms) and Fatigue Severity Scale (FSS) scores >4 (significant fatigue). Clinical severity (Eczema Area and Severity Index [EASI], objective Scoring Atopic Dermatitis [oSCORAD]), quality of life (DLQI), psychological symptoms, treatment needs and benefits (PNQ, PBI) and drug survival were assessed over 12 months. Among 633 patients, those with elevated baseline CES-D (n=309) or FSS (n=281) scores reported greater disease burden measured by DLQI, while EASI and oSCORAD did not differ between subgroups. Both CES-D and FSS scores decreased markedly within the first 3 months. Sleep and social functioning needs were more frequently reported in high-burden subgroups and more often fulfilled after 12 months. Drug survival was comparable across subgroups. Dupilumab treatment was associated with significant improvements in depressive symptoms, fatigue and skin severity. Patients with higher baseline mental health burden showed comparable improvements in patient relevant domains, supporting the broad relevance of dupilumab in real-world atopic dermatitis care.

Indexed as

Antibodies, Monoclonal, HumanizedDepressionDermatitis, AtopicFatigueAdultFemaleHumansLongitudinal StudiesMaleMiddle AgedQuality of LifeRegistriesSeverity of Illness IndexTime FactorsTreatment OutcomeYoung AdultAntibodies, Monoclonal, Humanizeddupilumab

Identifiers

PMID42563462
PMCPMC13446091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.